Detalhe da pesquisa
1.
Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study.
Breast Cancer Res Treat
; 143(3): 485-92, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24395109
2.
Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: results from North Central Cancer Treatment Group adjuvant trial N9831.
Cancer
; 119(15): 2675-82, 2013 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23744760
3.
Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005).
Breast Cancer Res Treat
; 138(1): 99-108, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23420271
4.
Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response.
Lancet Oncol
; 10(3): 267-77, 2009 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-19261255
5.
Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy.
Mol Cancer Ther
; 7(4): 944-51, 2008 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-18413808
6.
IGF1R Protein Expression Is Not Associated with Differential Benefit to Concurrent Trastuzumab in Early-Stage HER2+ Breast Cancer from the North Central Cancer Treatment Group (Alliance) Adjuvant Trastuzumab Trial N9831.
Clin Cancer Res
; 23(15): 4203-4211, 2017 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28533226
7.
Evaluation of a panel of tumor markers for molecular detection of circulating cancer cells in women with suspected breast cancer.
Clin Cancer Res
; 11(10): 3722-32, 2005 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-15897569
8.
Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial.
J Clin Oncol
; 33(7): 701-8, 2015 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25605861
9.
Quality assessment metrics for whole genome gene expression profiling of paraffin embedded samples.
BMC Res Notes
; 6: 33, 2013 Jan 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-23360712
10.
Impact of c-MYC protein expression on outcome of patients with early-stage HER2+ breast cancer treated with adjuvant trastuzumab NCCTG (alliance) N9831.
Clin Cancer Res
; 19(20): 5798-807, 2013 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23965903
11.
Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial.
J Clin Oncol
; 31(17): 2115-22, 2013 Jun 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-23650412
12.
Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria.
J Natl Cancer Inst
; 104(2): 159-62, 2012 Jan 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-22138096
13.
Cytokeratin-19 and mammaglobin gene expression in circulating tumor cells from metastatic breast cancer patients enrolled in North Central Cancer Treatment Group trials, N0234/336/436/437.
Clin Cancer Res
; 17(22): 7183-93, 2011 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-21976532
14.
C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial.
J Clin Oncol
; 29(6): 651-9, 2011 Feb 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-21245420
15.
Transforming growth factor-beta1 modulates insulin-like growth factor binding protein-4 expression and proteolysis in cultured periosteal explants.
Growth Horm IGF Res
; 20(2): 81-6, 2010 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-19656700
16.
Expression profiling of formalin-fixed paraffin-embedded primary breast tumors using cancer-specific and whole genome gene panels on the DASL® platform.
BMC Med Genomics
; 3: 60, 2010 Dec 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-21172013
17.
HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial.
J Clin Oncol
; 28(28): 4307-15, 2010 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-20697084
18.
A promising approach for treatment of tumor-induced bone diseases: utilizing bisphosphonate derivatives of nucleoside antimetabolites.
Bone
; 47(1): 12-22, 2010 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-20233612
19.
Overexpression of the TGF-beta antagonist Smad7 in endometrial cancer.
Gynecol Oncol
; 96(2): 368-73, 2005 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-15661223
20.
Differential gene expression of TGF-beta family members and osteopontin in breast tumor tissue: analysis by real-time quantitative PCR.
Breast Cancer Res Treat
; 74(3): 255-69, 2002 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-12206515